Introduction
============

Lung cancer is frequently accompanied by bone metastasis. A prospective observation study conducted in Japan revealed that bone metastasis was present at the time of diagnosis in 48% of patients with stage IV non-small-cell lung cancer (NSCLC) and in 40% of those with extensive-stage small-cell lung cancer ([@b1-mco-0-0-1903]). It has also been demonstrated that skeletal-related events (SREs) such as pain, bone fracture, and spinal cord compression in cases of bone metastases lower the patients\' quality of life and worsen their prognosis. In cases of lung cancer with bone metastases at an advanced stage, SREs are reportedly found in approximately 20--30% of cases at the time of diagnosis ([@b1-mco-0-0-1903]--[@b3-mco-0-0-1903]). The time between the occurrence of bone metastases and the onset of SREs is reportedly shorter in patients with lung cancer than in those with breast or prostate cancer. Therefore, it is important to initiate treatment as soon as possible after the diagnosis of bone metastases to prevent SREs.

Under normal conditions, osteoclasts resorb bone and release growth factors accumulated in the bone matrix, such as insulin-like growth factor (IGF) and transforming growth factor-β (TGF-β), into the marrow, thereby facilitating osteogenesis by osteoblasts. On the other hand, osteoblasts produce the receptor activator of nuclear factor κB ligand (RANKL), promote the differentiation of osteoclast precursors into osteoclasts, and activate mature osteoclasts. The process of this series of events is called bone remodeling. If cancer cells invade this environment, osteolysis by osteoclasts causes IGF and TGF-β to be released from the bone matrix in order to serve as growth factors for cancer cells. Cancer cells release cytokines such as parathyroid hormone-related peptide and prostaglandin E2, which subsequently induce the expression of RANKL. In turn, RANKL activates osteoclasts, and the activated osteoclasts accelerate bone resorption. This secures a space for cancer cells to proliferate and survive and allows IGF and TGF-β accumulated in the bone matrix to be released as a means to promote the proliferation of cancer cells. The proliferation of cancer cells increases cytokines that stimulate osteoblasts and further facilitates the activity of osteoclasts, creating a vicious cycle ([@b4-mco-0-0-1903]).

Bone-modifying agents (BMAs) aim to inhibit the progression of bone metastases and to reduce SREs by severing this vicious cycle of bone metastases. At present, BMAs used for lung cancer include the bisphosphonate zoledronic acid and denosumab, which is a monoclonal antibody for RANKL.

Zoledronic acid accumulates in the surface of the bone matrix and exerts its SRE-inhibiting action by causing apoptosis of osteoclasts that have incorporated zoledronic acid, thereby inhibiting bone resorption ([@b5-mco-0-0-1903],[@b6-mco-0-0-1903]). In a phase III randomized placebo-controlled trial in patients with solid cancers, including non-small cell lung cancer, the incidence rate of SREs (irradiation to bone, pathological fracture, surgical treatment of bone lesions, spinal cord compression, and hypercalcemia) by the 87th week was significantly decreased by administration of zoledronic acid ([@b7-mco-0-0-1903],[@b8-mco-0-0-1903]).

Based on the results of this study, administration of zoledronic acid in patients with lung cancer accompanied by bone metastases has become the standard treatment in daily clinical practice. The Japanese Society of Medical Oncology (JSMO) guidelines for the diagnosis and treatment of bone metastases also recommend this therapy. However, although osteonecrosis of the jaw (ONJ) is known as an adverse event of zoledronic acid therapy, there have been no comprehensive reports in the field of lung cancer. With this in mind, we conducted the present retrospective multi-center survey study to better understand the clinical course of NSCLC accompanied by bone metastases, paying particular attention to the frequency of ONJ, during a period when zoledronic acid was becoming widely used.

Materials and methods
=====================

### Patients

This study covered the observation period between January 2008 and December 2009, and included 12 medical facilities ([Table I](#tI-mco-0-0-1903){ref-type="table"}) that were routinely prescribing zoledronic acid for patients with NSCLC accompanied by bone metastases and that consented to cooperate in the study. All patients with NSCLC with bone metastases who received at least 2 doses of zoledronic acid were enrolled. The protocol was approved by the Clinical Trial Review Committee of the Thoracic Oncology Research Group (TORG) and the Institutional Review Board of TokyoMetropolitan Cancer and Infectious disease Center Komagome Hospital (September 13, 2010; approval no. 863) and by each participating institution. Due to the retrospective nature of the study, the requirement for written informed consent was waived.

The purpose of the study was to evaluate the incidence of ONJ. The study items included age, sex, performance status (PS), histological type, disease stage, treatment regimen, number of zoledronic acid doses, duration of zoledronic acid therapy, types of SREs, time until SRE occurrence, and presence/absence of ONJ.

SREs were defined as bone fracture, spinal cord compression (spinal paralysis), surgery for bone lesions, radiation therapy for bone lesions, and hypercalcemia.

### Statistical analysis

Differences in characteristics were evaluated using the χ^2^ test. Survival was estimated using the Kaplan-Meier method. All the tests were two-sided, and P\<0.05 was considered to indicate a statistically significant difference. All the data were analyzed using JMP software, version 10 (SAS Institute, Inc.).

Results
=======

A total of 198 patients were enrolled from the 12 facilities. [Table II](#tII-mco-0-0-1903){ref-type="table"} shows the patient characteristics. The subjects comprised 126 men and 72 women, with a median age of 64 (44--89) years. The histological type was adenocarcinoma in 131 patients, squamous cell carcinoma in 30, and not otherwise specified in 37. Seventy-eight patients had experienced SREs prior to the beginning of zoledronic acid therapy, whereas 120 patients had not. [Table III](#tIII-mco-0-0-1903){ref-type="table"} shows the regimens of zoledronic acid therapy. The median duration of zoledronic acid therapy was 106 days \[95% confidence interval (CI): 92--133 days\] in 196 patients, excluding two in whom data collection was not possible. The median number of zoledronic acid doses was 4 (2--41).

A breakdown of the SREs observed is shown in [Fig. 1](#f1-mco-0-0-1903){ref-type="fig"}. Overall, SREs occurred in 77 of 198 patients. The period of survival until the occurrence of the first SRE or death after zoledronic acid therapy (survival without SREs) was 202 (95% CI: 156--246) days ([Fig. 2](#f2-mco-0-0-1903){ref-type="fig"}). In relation to the presence or absence of a history of SREs prior to zoledronic acid therapy, SREs reoccurred during zoledronic acid therapy in 35 of 78 patients (45%) with a history of SREs, whereas SREs occurred in 42 of 120 patients (35%) without a history of SREs ([Fig. 1](#f1-mco-0-0-1903){ref-type="fig"}). There was no significant difference in the rate of SRE occurrence between the two groups (P=0.16). No ONJ occurred in any of the 198 patients (95% CI: 0--1.9%).

Discussion
==========

This study was a retrospective study in consecutively enrolled patients with advanced NSCLC with bone metastases who received zoledronic acid therapy. The median period of survival until the first SRE or death was 202 days. In a randomized study conducted by Rosen *et al* ([@b8-mco-0-0-1903]), the time to the first SRE was 236 days. In our study, the number of events was judged to be insufficient for analysis of the time to the first SRE, and the time to the first SRE, including death as an event, was therefore examined. A subgroup analysis of patients with NSCLC from the aforementioned randomized study showed that the median survival period was 177 days. Our present study showed a longer survival period, but this may have reflected the characteristic features of lung cancer in Japanese patients, who are often positive for driver gene mutations such as EGFR gene mutation. It has also been reported that the risk of SRE occurrence is decreased by 38% and that the time to the first SRE is significantly longer in patients on zoledronic acid therapy ([@b9-mco-0-0-1903]).

The-above mentioned subgroup analysis of the randomized controlled study also revealed that the risk of developing SREs was 1.41-fold higher in patients with a history of SREs than in those without such a history ([@b10-mco-0-0-1903]). In the study, the incidence rates of SREs after zoledronic acid therapy were 42 and 34% in patients with a history of SREs and in those without such a history. In our study, there was no significant difference in the incidence rate of SREs after the initiation of zoledronic acid therapy between patients who had prior SREs and those who did not. The incidence rates of SREs after zoledronic acid therapy in our study were similar to the-above mentioned analysis ([@b10-mco-0-0-1903]). In other words, our study showed that zoledronic acid has a certain level of efficacy regardless of the presence or absence of prior SREs.

In addition, Hirsh *et al* ([@b10-mco-0-0-1903]) reported that zoledronic acid is slightly more effective in patients with a history of SREs. More specifically, the risk of SREs was decreased by 31%, and the time to the first SRE was increased by 4 months in patients with a history of SREs, whereas the risk of SREs was decreased by 23% and the time to the first SRE was increased by 2.5 months in those without a history of SREs. We did not examine this issue because no randomization was used in this study ([@b10-mco-0-0-1903]).

In this study, ONJ was not found in any patient. ONJ associated with the administration of BMAs is defined as follows: The presence of bone fistula occurring from inside or outside the oral cavity or exposed bone persisting for at least 8 weeks in the mouth, jaw, or face area in patients who were on current or prior bone-modifying agent (BMA) therapy and who have no history of radiation therapy or evident metastatic lesions in the jawbone. Although rare, ONJ is a serious adverse event. It has been reported that the incidence rate of ONJ associated with the use of injectable bisphosphonate for bone metastases depends on the type of bisphosphonate agent, total dose, dosing period, and history of dental disease ([@b11-mco-0-0-1903]), and the incidence rate is particularly high, at 1.3%, when zoledronic acid, which contains nitrogen, is used ([@b12-mco-0-0-1903]). Risk factors of ONJ include invasive dental treatment applied to the bone such as tooth extraction, poor status of oral hygiene, periodontal disease, periodontal abscess, and a history of inflammatory disease such as apical periodontitis ([@b13-mco-0-0-1903]). It has been reported that proper management of oral hygiene reduces the risk of ONJ occurrence during BMA therapy, and it is thus recommended to routinely perform dental checkups and prophylactic dental procedures before the initiation of BMA therapy ([@b14-mco-0-0-1903]). All facilities that participated in this study were general hospitals that had full-time dentists who provided appropriate oral care at the time of zoledronic acid therapy. The degree of intervention by dentists are various between facilities. However, for example, dentists performed dental checkup for all patients before the administration of zoledronic acid in the Department of Thoracic Oncology and Respiratory Medicine, TokyoMetropolitan Cancer and Infectious disease Center Komagome Hospital. These interventions by expert dentists might have led to the lack of occurrence of ONJ among the subjects in this study. In addition, the longer the duration of the use of injectable bisphosphonate, the higher the risk of ONJ occurrence; the incidence rate of ONJ is reportedly 1.5% after 4--12 months of bisphosphonate therapy, whereas the corresponding rate is 7.7% after 27--48 months ([@b11-mco-0-0-1903]). In our study, the median duration of zoledronic acid therapy was only 106 days, and this may be another reason for why there was no occurrence of ONJ.

This study has some limitations. First, this was a retrospective study including a small number of patients. Second, this study did not use a randomized design in relation to the presence or absence of zoledronic acid therapy. Third, the duration of zoledronic acid therapy was short for the clinical situation of Japanese patients, in whom the involvement of driver mutations is frequent. Fourth, this study did not include the data about the treatment for lung cancer and the lesion and radiologic appearance of bone metastases.

Despite these limitations, we consider that this study is valuable, because the clinical course of NSCLC accompanied by bone metastases and the related occurrence of ONJ have rarely been reported in a comprehensive manner since BMAs have become widely used. In the treatment of NSCLC, many novel drugs, including new molecular-targeted drugs, immune checkpoint inhibitors, and angiogenesis inhibitors, are currently available, achieving marked prolongation of survival. However, the development of new drugs for bone metastases has been limited, and it is expected that zoledronic acid will continue to play an important role in the treatment of bone metastases. In this regard, further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of zoledronic acid therapy seems to be particularly important.

Our study showed that zoledronic acid has a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of zoledronic acid therapy was short in this study, further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of zoledronic acid therapy seems to be particularly important.
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![SRE with or without history of SRE prior to ZA administration. Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45%) subsequently experienced SRE following the commencement of ZA treatment. On the other hand, among the 120 patients without a history of SRE prior to starting ZA treatment, 42 (35%) experienced SRE after the start of ZA administration. SRE, skeletal-related event; ZA, zoledronic acid.](mco-11-04-0349-g00){#f1-mco-0-0-1903}

![Time to first SRE in patients who experienced SRE following ZA treatment. The median time to the first SRE was 202 days (95% CI, 156--264 days) in patients who experienced SRE following ZA treatment. SRE, skeletal-related event; CI, confidence interval; ZA, zoledronic acid.](mco-11-04-0349-g01){#f2-mco-0-0-1903}

###### 

Institutions involved in the study.

  Institution name                                                            No. of patients recruited
  --------------------------------------------------------------------------- ---------------------------
  Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital   34
  Keio University School of Medicine                                          26
  Shikoku Cancer center                                                       25
  Yokohama Municipal Citizen\'s Hospital                                      24
  Tokyo Medical University                                                    18
  Kitasato University School of Medicine                                      15
  Fujisawa city hospital                                                      14
  National Kyushu Cancer Center                                               14
  Gunma Prefectural Cancer Center                                             10
  Graduate School of Medicine, Chiba University                               7
  Teikyo University School of Medicine                                        5
  Kanagawa Cancer Center                                                      4

###### 

Patients characteristics.

  Characteristics             No. of patients
  --------------------------- -----------------
  Total no. of patients       198
  Sex                         
    Male                      126
    Female                    72
  Age, years                  
    Median                    64
    Range                     44--89
  Histology                   
    Adenocarcinoma            131
    Squamous cell carcinoma   30
    NSCLC-NOS                 37
  Prior SREs                  
    No                        120
    Yes                       78

NSCLC-NOS, non-small-cell lung cancer-not otherwise specified; SREs, skeletal-related events.

###### 

Duration and number of ZA administrations.

  Variable                Duration of ZA administration   No. of ZA administrations
  ----------------------- ------------------------------- ---------------------------
  Total no. of patients   196                             197
  Median, days or n       106                             4
  Range, days             --                              2--41
  95% CI                  92--133                         --

ZA, zoledronic acid; CI, confidence interval.
